CRISPR Therapeutics AG
CRSP
$43.34
-$2.19-4.81%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 56.59% | 32.01% | -8.42% | -230.49% | 179.67% |
| Total Depreciation and Amortization | 2.17% | -2.19% | 0.25% | -1.37% | -0.51% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -53.63% | -5.45% | 40.57% | -19.29% | -7.80% |
| Change in Net Operating Assets | 39.65% | -484.71% | -95.02% | 203.19% | -488.06% |
| Cash from Operations | 53.20% | -11.85% | -187.09% | 214.24% | -141.05% |
| Capital Expenditure | -15.98% | 69.02% | 1.94% | 2.30% | 65.16% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 165.73% | -27.88% | -30.00% | -20.27% | -165.37% |
| Cash from Investing | 165.49% | -27.34% | -29.76% | -20.07% | -167.12% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 75.06% | -- | -- | 685.68% | 2,402.51% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 75.06% | 2,168.67% | -100.15% | 685.68% | 2,402.51% |
| Foreign Exchange rate Adjustments | -216.00% | 3,650.00% | 118.18% | -118.03% | 227.08% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 128.05% | -16.08% | -170.14% | 329.47% | -266.90% |
